Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2016
17th World Conference on Lung Cancer
Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria
Presentation Date(s):- Dec 4 - 7, 2016
- Total Presentations: 2466
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
OA03 - Immunotherapy Checkpoint Inhibitors in Advanced NSCLC
- Type: Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 8
- Moderators:L. Crinò
- Coordinates: 12/05/2016, 11:00 - 12:30, Hall C8
-
+
OA03.05 - Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 (Abstract under Embargo until December 5, 7:00 CET)
11:45 - 11:55 | Author(s): S. Peters
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA04 - HER2, P53, KRAS and Other Targets in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:B. Han
- Coordinates: 12/05/2016, 16:00 - 17:30, Lehar 3-4
-
+
MA04.02 - Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study
16:06 - 16:12 | Author(s): L. Gandhi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA10 - EGFR Mutations
- Type: Oral Session
- Track: Biology/Pathology
- Presentations: 8
- Moderators:J. Spicer
- Coordinates: 12/06/2016, 11:00 - 12:30, Strauss 1
-
+
OA10.06 - Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study)
11:55 - 12:05 | Author(s): N. Guibert
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA11 - Angiogenesis in Advanced Lung Cancer
- Type: Oral Session
- Track: Advanced NSCLC
- Presentations: 8
- Moderators:L.M. Montuenga
- Coordinates: 12/06/2016, 11:00 - 12:30, Stolz 2
-
+
OA11.01 - Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study
11:00 - 11:10 | Author(s): A.B. Cortot
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
ISS10 - Industry Supported Symposium: Novel Treatment Strategies for ALK+ NSCLC: From Evidence to Practice – Novartis Oncology
- Type: Industry Supported Symposium
- Track:
- Presentations: 6
- Moderators:S. Peters
- Coordinates: 12/06/2016, 12:45 - 14:15, Lehar 3-4
-
+
ISS10.03 - Optimizing Outcomes for Your ALK+ NSCLC Patients
13:05 - 13:20 | Author(s): F. Barlesi
- Abstract
No abstract available for this presentation
-
+
ISS10.05 - Panel Discussion: Challenges in Sequencing Therapy for Your ALK+ NSCLC Patients
13:30 - 14:00 | Author(s): S. Peters
- Abstract
No abstract available for this presentation
-
+
P2.03b - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 98
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03b-031 - Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC
14:30 - 14:30 | Author(s): P. Jänne
- Abstract
Loading... -
+
P2.03b-037 - Prognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study
14:30 - 14:30 | Author(s): J. Cadranel
- Abstract
Loading...
-
+
PL04a - Plenary Session: Immune Checkpoint Inhibitors in Advanced NSCLC
- Type: Plenary
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 5
- Moderators:J. Soria
- Coordinates: 12/07/2016, 08:45 - 09:40, Hall D (Plenary Hall)
-
+
PL04a.02 - OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses (Abstract under Embargo until December 7, 7:00 CET)
08:55 - 09:05 | Author(s): S.M. Gadgeel
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.02a - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 37
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02a-016 - Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC)
14:30 - 14:30 | Author(s): J.C. Yang
- Abstract
Loading... -
+
P3.02a-034 - Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial
14:30 - 14:30 | Author(s): J. Mazieres
- Abstract
Loading...
-
+
P3.02b - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 126
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-062 - Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
14:30 - 14:30 | Author(s): B. Besse
- Abstract
Loading... -
+
P3.02b-117 - Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
14:30 - 14:30 | Author(s): D. Tan
- Abstract
Loading...
-
+
P3.02c - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 103
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02c-032 - Interstitial Pneumonitis Associated with Immune Checkpoint Inhibitors Treatment in Cancer Patients
14:30 - 14:30 | Author(s): M. Delaunay
- Abstract
Loading...
